Perioperative Chemotherapy for Gastro-Esophageal or Gastric Cancer: Anthracyclin Triplets versus FLOT

被引:0
|
作者
Geerts, Julie F. M. [1 ,2 ]
van der Zijden, Charlene J. [2 ]
van der Sluis, Pieter C. [2 ]
Spaander, Manon C. W. [3 ]
Nieuwenhuijzen, Grard A. P. [1 ]
Rosman, Camiel [4 ]
van Laarhoven, Hanneke W. M. [5 ,6 ]
Verhoeven, Rob H. A. [5 ,6 ,7 ]
Wijnhoven, Bas P. L. [2 ]
Lagarde, Sjoerd M. [2 ]
Mostert, Bianca [8 ]
机构
[1] Catharina Hosp, Dept Surg, NL-5623 EJ Eindhoven, Netherlands
[2] Erasmus MC, Dept Surg, Canc Inst, NL-3015 GD Rotterdam, Netherlands
[3] Erasmus MC, Dept Gastroenterol & Hepatol, NL-3015 GD Rotterdam, Netherlands
[4] Radboud Univ Nijmegen, Dept Surg, Med Ctr, NL-6525 GA Nijmegen, Netherlands
[5] Univ Amsterdam, Dept Med Oncol, Amsterdam UMC Locat, NL-1081 HV Amsterdam, Netherlands
[6] Canc Ctr Amsterdam, Canc Treatment & Qual Life, NL-1105 AZ Amsterdam, Netherlands
[7] Netherlands Comprehens Canc Org IKNL, Dept Res & Dev, NL-3511 LC Utrecht, Netherlands
[8] Erasmus MC, Dept Med Oncol, Canc Inst, NL-3015 GD Rotterdam, Netherlands
关键词
esophageal cancer; gastro-esophageal cancer; gastric cancer; neoadjuvant chemotherapy; esophagectomy; STAGING LAPAROSCOPY; ADENOCARCINOMA; SURVIVAL; 5-FLUOROURACIL; CAPECITABINE; OXALIPLATIN;
D O I
10.3390/cancers16071291
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The FLOT4-AIO trial (2019) showed improved survival with perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) compared to anthracyclin triplets in gastric cancer treatment. It is unclear whether these results extend to real-world scenarios in the Netherlands. This study aimed to compare outcomes of perioperative FLOT to anthracyclin triplets in a real-world Dutch gastric cancer population. Methods: Patients diagnosed with resectable (cT2-4a/cTxN0-3/NxM0) gastric or gastro-esophageal junction carcinoma between 2015-2021 who received neoadjuvant FLOT or anthracyclin triplets were selected from the Netherlands Cancer Registry. The primary outcome was overall survival (OS), analyzed through multivariable Cox regression. Secondary outcomes included pathological complete response (pCR), neoadjuvant chemotherapy cycle completion, surgical resection rates, and adjuvant therapy. Results: Adjusted OS showed no significant survival benefit (HR = 0.88, 95% CI 0.77-1.01, p = 0.07), even though the median OS was numerically improved by 8 months with FLOT compared to anthracyclin triplets (48.1 vs. 39.9 months, p = 0.16). FLOT patients were more likely to undergo diagnostic staging laparoscopies (74.2% vs. 44.1%, p < 0.001), had higher rates of completing neoadjuvant chemotherapy (OR = 1.35, 95% CI 1.09-1.68, p = 0.007), receiving adjuvant therapy (OR = 1.34, 95% CI 1.08-1.66, p = 0.08), and achieving pCR (OR = 1.52, 95% CI 1.05-2.20, p = 0.03). No significant differences were observed in (radical) resection rates. Conclusion(s): Real-world data showed no significant OS improvement for FLOT-treated patients compared to anthracyclin triplets, despite more staging laparoscopies. However, FLOT patients demonstrated higher rates of neoadjuvant therapy completion, proceeding to adjuvant therapy, and increased pCR rates. Therefore, we recommend the continued use of neoadjuvant FLOT therapy in the current clinical setting.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Gastric emptying, transient les relaxations and gastro-esophageal reflux
    Sifrim, D
    Holloway, RH
    Tack, J
    Geypens, B
    Luypaerts, A
    Janssens, J
    GASTROENTEROLOGY, 1999, 116 (04) : A313 - A313
  • [42] PACLITAXEL AS SECOND-LINE CHEMOTHERAPY IN ADVANCED OR RECURRENT GASTRIC AND GASTRO-ESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
    Machado, Karime
    Toloi, Diego
    Nebuloni, Daniela
    Ribeiro, Suilane
    Riechelmann, Rachel
    Fukushima, Julia
    Freitas, Helano
    Hoff, Paulo
    ANNALS OF ONCOLOGY, 2011, 22 : v48 - v49
  • [43] Updated results of perioperative PD-1 antibody toripalimab plus FLOT chemotherapy for locally advanced resectable gastric or gastro-esophageal junction adenocarcinoma: A one-arm open-table phase II trial
    Li, Hongli
    Ge, Shaohua
    Zang, Fenglin
    Ren, Peng
    Cao, Fuliang
    Liu, Rui
    Yang, Yuchong
    Ning, Tao
    Bai, Ming
    Wang, Xia
    Ji, Zhi
    Duan, Jingjing
    Liang, Han
    Ba, Yi
    Deng, Ting
    Deng, Jingyu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] Obesity Does Not Affect Outcomes in Gastro-Esophageal Cancer
    Farmer, Russell
    McMasters, Kelly M.
    Scoggins, Charles R.
    Martin, Robert C.
    GASTROENTEROLOGY, 2011, 140 (05) : S1033 - S1034
  • [45] Gastro-esophageal isoperistaltic bypass in the palliation of irresectable thoracic esophageal cancer
    Alcantara, PSM
    SpencerNetto, FAC
    Silva, JF
    Soares, LA
    Pollara, WM
    Bevilacqua, RG
    INTERNATIONAL SURGERY, 1997, 82 (03) : 249 - 253
  • [46] MicroRNAs as biomarkers of resistance to HER2 inhibition in combination with chemotherapy in gastro-esophageal cancer
    Lote, Hazel
    Lampis, Andrea
    Vlachogiannis, George
    Hahne, Jens
    Moorcraft, Sing-Yu
    Davidson, Michael
    Fong, Carolin
    Begum, Ruwaida
    Fassan, Matteo
    Rao, Sheela
    Watkins, David
    Starling, Naureen
    Chau, Ian
    Cunningham, David
    Valeri, Nicola
    CANCER RESEARCH, 2020, 80 (16)
  • [47] Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial (Jan, 10.1038/s41591-023-02721-w, 2024)
    Yuan, Shu-Qiang
    Nie, Run-Cong
    Jin, Ying
    Liang, Cheng-Cai
    Li, Yuan-Fang
    Jian, Rui
    Sun, Xiao-Wei
    Chen, Ying-Bo
    Guan, Wen-Long
    Wang, Zi-Xian
    Qiu, Hai-Bo
    Wang, Wei
    Chen, Shi
    Zhang, Dong-Sheng
    Ling, Yi-Hong
    Xi, Shao-Yan
    Cai, Mu-Yan
    Huang, Chun-Yu
    Yang, Qiu-Xia
    Liu, Zhi-Min
    Guan, Yuan-Xiang
    Chen, Yong-Ming
    Li, Ji-Bin
    Tang, Xiong-Wen
    Peng, Jun-Sheng
    Zhou, Zhi-Wei
    Xu, Rui-Hua
    Wang, Feng
    NATURE MEDICINE, 2024, 30 (2) : 605 - 605
  • [48] Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer
    Gullo, Irene
    Grillo, Federica
    Molinaro, Luca
    Fassan, Matteo
    De Silvestri, Annalisa
    Tinelli, Carmine
    Rugge, Massimo
    Fiocca, Roberto
    Mastracci, Luca
    ENDOSCOPY INTERNATIONAL OPEN, 2015, 3 (02) : E165 - E170
  • [49] Adenocarcinoma of the gastro-esophageal junction: CT for monitoring during neoadjuvant chemotherapy
    Helmberger, H
    Baum, U
    Dittler, HJ
    Sendler, A
    Schulte, B
    Herter, B
    Fink, U
    Gerhardt, P
    EUROPEAN JOURNAL OF RADIOLOGY, 1996, 23 (02) : 107 - 110
  • [50] ESOPHAGEAL CANCER - PERIOPERATIVE CHEMOTHERAPY
    FINK, U
    RIES, G
    SIEWERT, JR
    LANGENBECKS ARCHIV FUR CHIRURGIE, 1987, 372 : 145 - 148